Copyright
©The Author(s) 2017.
World J Gastroenterol. Feb 28, 2017; 23(8): 1489-1496
Published online Feb 28, 2017. doi: 10.3748/wjg.v23.i8.1489
Published online Feb 28, 2017. doi: 10.3748/wjg.v23.i8.1489
Table 1 Demographics and baseline characteristics of the 138 South Korean patients in this study with Crohn’s disease who received infliximab treatment n (%)
| Variables | Value |
| Male/female | 90/48 (65.2/34.8) |
| Median age at diagnosis (IQR) (yr) | 21 (19-27) |
| Median age at first infusion (IQR) (yr) | 27 (22-33) |
| Median duration of disease prior to first IFX (IQR) (mo) | 52 (13-91) |
| Indication for IFX treatment | |
| Luminal | 122 (88.4) |
| Perianal fistulizing | 16 (11.6) |
| Median follow-up of IFX treatment (IQR) (mo) | 47 (30-73) |
| Disease location at diagnosis | |
| L1 (ileum) | 19 (13.8) |
| L2 (colon) | 9 (6.5) |
| L3 (ileocolon) | 108 (78.3) |
| Not documented | 2 (1.4) |
| Disease behavior at diagnosis | |
| B1 (non-stricturing non-penetrating) | 115 (83.3) |
| B2 (stricturing) | 7 (5.1) |
| B3 (penetrating) | 16 (11.6) |
| Perianal fistula at diagnosis | |
| Active | 36 (26.1) |
| Previous | 26 (18.8) |
| Smoking status at diagnosis | |
| Current smoker | 26 (18.8) |
| Ex-smoker | 9 (6.6) |
| Never smoker | 103 (74.6) |
| Previous major abdominal surgery prior to first IFX | 44 (31.9) |
| Concomitant immunomodulators | |
| None | 73 (52.9) |
| Azathioprine/6-mercaptopurine | 64 (46.4) |
| Methotrexate | 1 (0.7) |
- Citation: Oh EH, Ko DH, Seo H, Chang K, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease. World J Gastroenterol 2017; 23(8): 1489-1496
- URL: https://www.wjgnet.com/1007-9327/full/v23/i8/1489.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i8.1489